Novozymes A/S – (NVZMY) to Post FY2018 Earnings of $1.75 Per Share, Jefferies Group Forecasts

Novozymes A/S – (OTCMKTS:NVZMY) – Investment analysts at Jefferies Group reduced their FY2018 EPS estimates for Novozymes A/S in a research report issued to clients and investors on Thursday. Jefferies Group analyst L. Alexander now anticipates that the biotechnology company will earn $1.75 per share for the year, down from their previous estimate of $1.85. Jefferies Group has a “Hold” rating and a $54.97 price objective on the stock.

Separately, Zacks Investment Research downgraded shares of Novozymes A/S from a “buy” rating to a “hold” rating in a research report on Wednesday, December 27th.

Shares of Novozymes A/S (OTCMKTS:NVZMY) opened at $48.69 on Monday. Novozymes A/S has a 12-month low of $37.73 and a 12-month high of $57.84. The stock has a market cap of $12,233.65, a P/E ratio of 30.43, a price-to-earnings-growth ratio of 2.11 and a beta of 0.90.

Novozymes A/S (OTCMKTS:NVZMY) last released its earnings results on Wednesday, February 7th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.03). Novozymes A/S had a return on equity of 29.35% and a net margin of 21.50%. The company had revenue of $581.18 million during the quarter. WARNING: This piece was originally reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at

Novozymes A/S Company Profile

Novozymes A/S is a Denmark-based biotechnology company engaged in the production and sale of industrial enzymes, microorganisms and biopharmaceutical ingredients. The Company operates in four geographical regions: Europe, Middle East & Africa (including Denmark), North America, Asia Pacific and Latin America.

Receive News & Ratings for Novozymes A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novozymes A/S and related companies with's FREE daily email newsletter.

Leave a Reply